Eli Lilly's Weight Loss Portfolio Generates $10 Billion in Quarterly Revenue
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 19 2026
0mins
Source: NASDAQ.COM
- Market Leadership: Eli Lilly's leadership in the weight loss drug market has resulted in its weight loss portfolio generating $10 billion in revenue in the latest quarter, driving overall revenue growth in double digits and demonstrating strong performance in a high-demand sector.
- Product Innovation Potential: Eli Lilly plans to launch the oral weight loss drug orforglipron, which is expected to further enhance market share due to its convenience and lower manufacturing costs compared to injectables, potentially attracting more patients.
- Sustained Demand Growth: High demand for Lilly's injectable drugs has led to shortages, prompting the company to expand its manufacturing capacity to meet the growing market needs, with analysts predicting the obesity drug market will approach $100 billion by 2030.
- Competitive Advantage: Although Novo Nordisk's weight loss pill has been approved, Lilly's orforglipron, which does not require dietary restrictions, may be easier for patients to incorporate into their daily routines, potentially capturing a larger market share and further solidifying its market position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 954.520
Low
950.00
Averages
1192
High
1500
Current: 954.520
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Launches New Obesity Drug Foundayo
- FDA Approval: Eli Lilly's Foundayo™ (orforglipron) has received FDA approval, specifically designed for adults with obesity or overweight and related medical issues, which is expected to significantly enhance patient weight management outcomes.
- Significant Weight Loss: In the ATTAIN-1 clinical trial, participants on the highest dose lost an average of 27.3 pounds (12.4%), compared to just 2.2 pounds (0.9%) in the placebo group, demonstrating Foundayo's efficacy and market potential.
- Convenient Access: Foundayo will be available through LillyDirect®, with commercial insurance patients paying only $25 per month and self-pay patients at $149, which is expected to improve drug accessibility and meet the needs of obesity patients.
- Global Rollout Plan: Lilly plans to launch Foundayo in over 40 countries shortly after approval, aiming to enhance the quality of life for obesity patients worldwide by providing effective treatment options.
See More
U.S. Stocks Open Lower Before Midday Recovery Amid Iran Conflict
- Market Volatility: On April 2, 2026, U.S. stocks opened lower before recovering slightly, with the Dow Jones Industrial Average struggling to find direction for most of the morning, reflecting market uncertainty.
- Tesla Delivery Miss: Tesla reported first-quarter deliveries of 358,023 vehicles, falling short of Wall Street's expectation of 366,000, resulting in a more than 5% drop in its stock price, which negatively impacted overall market sentiment.
- Surge in Oil Prices: Crude oil prices surged approximately 10% on Thursday due to ongoing tensions in Iran, with market participants anxious about supply disruptions in the Strait of Hormuz, although reports indicated Iran and Oman are working to restore traffic through the strait.
- Healthcare Stocks React: The Trump administration's plans to impose tariffs of up to 100% on certain imported pharmaceuticals led to a roughly 2% decline in healthcare stocks, including major players like Eli Lilly and Amgen, highlighting the market's sensitivity to policy changes.
See More
U.S. Stocks Recover Midday as Oil Prices Surge 10%
- Oil Price Surge: On Thursday, U.S. oil prices jumped approximately 10%, primarily due to President Trump's speech failing to provide a clear exit strategy from the Iran conflict, which left investors anxious about the trajectory of oil prices and significantly impacted overall market sentiment.
- Increased Market Volatility: Although all three major indexes recovered to near breakeven after sharp morning losses, Tesla's first-quarter delivery of 358,023 vehicles fell short of the expected 366,000, indicating pressure in the electric vehicle market and further exacerbating investor uncertainty.
- Iran-Oman Protocol Progress: Reports surfaced that Iran and Oman are drafting a protocol to restore some traffic through the Strait of Hormuz, which helped stocks rebound from early lows, although the lack of a clear resolution path for the conflict limited the overall rebound strength.
- Caution for Long-term Investors: The current market faces dual pressures from elevated oil prices and rising mortgage rates for five consecutive weeks, with analysts revisiting the uncomfortable term
See More
Ro Partners with Eli Lilly to Launch KwikPen Injection Device
- Product Collaboration Launch: Ro has partnered with Eli Lilly to introduce KwikPen, a prefilled injection pen containing multiple doses of the weight loss drug Zepbound, addressing the growing market demand for obesity treatments.
- FDA Approval and Market Introduction: KwikPen received FDA approval earlier this year and was launched on Lilly's direct-to-consumer site in February, with the lowest dose priced at $299 per month, reflecting the company's focus on the consumer market.
- Delivery Service Innovation: Amazon Pharmacy began offering same-day delivery for KwikPen in March, enhancing consumer convenience and potentially driving sales growth.
- Multi-Dose Pricing Strategy: Ro is launching the multi-dose KwikPen for cash-paying customers, with starter doses of 2.5 mg and 5 mg priced at $299 and $399 per month, respectively, and patients completing refills within 45 days can access higher doses at discounted rates, showcasing the company's pricing strategy flexibility.
See More
Trump Administration Plans 100% Tariffs on Imported Pharmaceuticals
- Tariff Policy Shift: The Trump administration is preparing to impose tariffs of up to 100% on branded drugs from companies that have not negotiated price reductions, potentially impacting major pharmaceutical firms like Eli Lilly, Pfizer, and Novo Nordisk, thereby increasing price volatility in the drug market.
- Manufacturing Incentives: Drugmakers can reduce or avoid tariffs by relocating production to the U.S. or negotiating deals with the administration, aiming to stimulate domestic manufacturing and potentially leading to a resurgence of investments in the pharmaceutical sector.
- Tariff Implementation Details: The draft proposal includes a 20% tariff for companies planning to onshore production, escalating to 100% in four years, which could significantly influence the long-term strategic positioning of the pharmaceutical industry.
- National Security Considerations: The tariff proposal stems from a Commerce Department investigation that identified certain pharmaceutical imports as a national security risk, highlighting the government's heightened focus on the security of drug supply chains.
See More
Trump Administration Plans New Tariffs on Pharmaceuticals
- New Tariff Policy: The Trump administration is preparing to impose new tariffs on pharmaceutical companies that have not struck price reduction deals, with patented drugs facing a potential 100% tariff, which could significantly increase costs and impact drug pricing.
- Exemption Pathways: Drugmakers can reduce or avoid tariffs by relocating production to the U.S. or negotiating agreements with the administration, aiming to encourage domestic manufacturing while potentially reshaping drug supply chains.
- Scope of Impact: Since November, over a dozen major drugmakers, including Eli Lilly, Pfizer, and Novo Nordisk, have secured three-year tariff exemptions through agreements with Trump, indicating a strong governmental stance on drug pricing that may alter competitive dynamics in the industry.
- Future Tariff Plans: The draft outlines a 20% tariff for companies planning to onshore production, escalating to 100% in four years, which could have profound implications for the pharmaceutical sector's long-term strategies amid increasing global market competition.
See More
Eli Lilly Launches New Obesity Drug Foundayo
- FDA Approval: Eli Lilly's Foundayo™ (orforglipron) has received FDA approval, specifically designed for adults with obesity or overweight and related medical issues, which is expected to significantly enhance patient weight management outcomes.
- Significant Weight Loss: In the ATTAIN-1 clinical trial, participants on the highest dose lost an average of 27.3 pounds (12.4%), compared to just 2.2 pounds (0.9%) in the placebo group, demonstrating Foundayo's efficacy and market potential.
- Convenient Access: Foundayo will be available through LillyDirect®, with commercial insurance patients paying only $25 per month and self-pay patients at $149, which is expected to improve drug accessibility and meet the needs of obesity patients.
- Global Rollout Plan: Lilly plans to launch Foundayo in over 40 countries shortly after approval, aiming to enhance the quality of life for obesity patients worldwide by providing effective treatment options.
See More
U.S. Stocks Open Lower Before Midday Recovery Amid Iran Conflict
- Market Volatility: On April 2, 2026, U.S. stocks opened lower before recovering slightly, with the Dow Jones Industrial Average struggling to find direction for most of the morning, reflecting market uncertainty.
- Tesla Delivery Miss: Tesla reported first-quarter deliveries of 358,023 vehicles, falling short of Wall Street's expectation of 366,000, resulting in a more than 5% drop in its stock price, which negatively impacted overall market sentiment.
- Surge in Oil Prices: Crude oil prices surged approximately 10% on Thursday due to ongoing tensions in Iran, with market participants anxious about supply disruptions in the Strait of Hormuz, although reports indicated Iran and Oman are working to restore traffic through the strait.
- Healthcare Stocks React: The Trump administration's plans to impose tariffs of up to 100% on certain imported pharmaceuticals led to a roughly 2% decline in healthcare stocks, including major players like Eli Lilly and Amgen, highlighting the market's sensitivity to policy changes.
See More
U.S. Stocks Recover Midday as Oil Prices Surge 10%
- Oil Price Surge: On Thursday, U.S. oil prices jumped approximately 10%, primarily due to President Trump's speech failing to provide a clear exit strategy from the Iran conflict, which left investors anxious about the trajectory of oil prices and significantly impacted overall market sentiment.
- Increased Market Volatility: Although all three major indexes recovered to near breakeven after sharp morning losses, Tesla's first-quarter delivery of 358,023 vehicles fell short of the expected 366,000, indicating pressure in the electric vehicle market and further exacerbating investor uncertainty.
- Iran-Oman Protocol Progress: Reports surfaced that Iran and Oman are drafting a protocol to restore some traffic through the Strait of Hormuz, which helped stocks rebound from early lows, although the lack of a clear resolution path for the conflict limited the overall rebound strength.
- Caution for Long-term Investors: The current market faces dual pressures from elevated oil prices and rising mortgage rates for five consecutive weeks, with analysts revisiting the uncomfortable term
See More
Ro Partners with Eli Lilly to Launch KwikPen Injection Device
- Product Collaboration Launch: Ro has partnered with Eli Lilly to introduce KwikPen, a prefilled injection pen containing multiple doses of the weight loss drug Zepbound, addressing the growing market demand for obesity treatments.
- FDA Approval and Market Introduction: KwikPen received FDA approval earlier this year and was launched on Lilly's direct-to-consumer site in February, with the lowest dose priced at $299 per month, reflecting the company's focus on the consumer market.
- Delivery Service Innovation: Amazon Pharmacy began offering same-day delivery for KwikPen in March, enhancing consumer convenience and potentially driving sales growth.
- Multi-Dose Pricing Strategy: Ro is launching the multi-dose KwikPen for cash-paying customers, with starter doses of 2.5 mg and 5 mg priced at $299 and $399 per month, respectively, and patients completing refills within 45 days can access higher doses at discounted rates, showcasing the company's pricing strategy flexibility.
See More
Trump Administration Plans 100% Tariffs on Imported Pharmaceuticals
- Tariff Policy Shift: The Trump administration is preparing to impose tariffs of up to 100% on branded drugs from companies that have not negotiated price reductions, potentially impacting major pharmaceutical firms like Eli Lilly, Pfizer, and Novo Nordisk, thereby increasing price volatility in the drug market.
- Manufacturing Incentives: Drugmakers can reduce or avoid tariffs by relocating production to the U.S. or negotiating deals with the administration, aiming to stimulate domestic manufacturing and potentially leading to a resurgence of investments in the pharmaceutical sector.
- Tariff Implementation Details: The draft proposal includes a 20% tariff for companies planning to onshore production, escalating to 100% in four years, which could significantly influence the long-term strategic positioning of the pharmaceutical industry.
- National Security Considerations: The tariff proposal stems from a Commerce Department investigation that identified certain pharmaceutical imports as a national security risk, highlighting the government's heightened focus on the security of drug supply chains.
See More
Trump Administration Plans New Tariffs on Pharmaceuticals
- New Tariff Policy: The Trump administration is preparing to impose new tariffs on pharmaceutical companies that have not struck price reduction deals, with patented drugs facing a potential 100% tariff, which could significantly increase costs and impact drug pricing.
- Exemption Pathways: Drugmakers can reduce or avoid tariffs by relocating production to the U.S. or negotiating agreements with the administration, aiming to encourage domestic manufacturing while potentially reshaping drug supply chains.
- Scope of Impact: Since November, over a dozen major drugmakers, including Eli Lilly, Pfizer, and Novo Nordisk, have secured three-year tariff exemptions through agreements with Trump, indicating a strong governmental stance on drug pricing that may alter competitive dynamics in the industry.
- Future Tariff Plans: The draft outlines a 20% tariff for companies planning to onshore production, escalating to 100% in four years, which could have profound implications for the pharmaceutical sector's long-term strategies amid increasing global market competition.
See More
